# Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

> **NCT05207865** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 441 (actual)

## Conditions studied

- Migraine
- Episodic Migraine
- Phonophobia
- Photophobia

## Interventions

- **DRUG:** Rimegepant

## Key facts

- **NCT ID:** NCT05207865
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-15
- **Primary completion:** 2024-07-02
- **Final completion:** 2024-07-02
- **Target enrollment:** 441 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05207865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05207865, "Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05207865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*